Global Liquid Biopsy Market is estimated to witness a lucrative CAGR of 17% by 2026

Liquid Biopsy is a procedure of sampling and analyzing non-solid biological tissues (such as blood and others), for the screening of cancer and other inflammatory conditions, associated with cardiac and other medical disorders. The sampling procedures are minimally invasive, quick and incur minimal patient pain and risk. Liquid Biopsy also helps in the early diagnosis of various types of cancers such as breast cancer, non-small cell lung carcinoma, lymphomas, head and neck cancer, and leukemia.

Advent of Advanced Technologies for Liquid Biopsy Drives the Global Market

Liquid biopsy is an emerging technology and has the potential to revolutionize early cancer detection by analyzing available ctDNA for specific mutation profiles, fragmentation patterns, and methylation signatures. The significant developments in a digital polymerase chain reaction (PCR) and next-generation sequencing (NGS) technologies has led to a significant reduction in sequencing cost with the improvement in the accuracy of liquid biopsy. Further advancements in technology are expected to trigger the growth of the market in the coming years.

Growing Adoption of Circulating Biomarkers for Early Detection & Screening of Cancer

Currently,  circulating cell-free DNA (cfDNA) and circulating tumor cells (CTCs) are the most commonly used liquid biopsy-derived biomarkers. In the recent years, CTCs have gained immense significance in detecting tumors, replacing invasive tissue biopsies not only due to their ease in sampling but also in providing data regarding tumor conditions in a ‘real-time’ manner. CTCs can also be used in vivo for the generation of patient-derived tumor models that assist in treatments.

“Liquid Biopsy is a dynamic and continuously evolving field. Technological advancements directed towards faster and more convenient diagnosis will drive the market. Liquid biopsies could be a game-changer in cancer testing.” - Head of Diagnostic Biomarkers, Liquid Biopsy Company, United States

North America Leads the Adoption of Liquid Biopsy Market

From a geographical perspective, North America holds the largest market share of the liquid biopsy market. The rising prevalence of cancer cases among the population in US, increased adoption of liquid biopsy for the diagnosis of cancer, higher patient preference for non-invasive diagnosis and monitoring and the presence of key players in this region are some of the key factors driving the market growth.

Competitive Landscape Analysis: Global Liquid Biopsy Market

Some of the top players operating in the global liquid biopsy market are F. Hoffmann-La Roche Ltd., Myriad Genetics Inc., QIAGEN N.V., Thermo Fisher Scientific Inc., Guardant Health Inc., MDxHealth SA, and Illumina Inc., among others.

Companies Adopting Inorganic Growth Strategies to Increase their Market Share

Players operating in the liquid biopsy market are adopting both organic and inorganic growth strategies such as collaborations, acquisitions, and new product launches to garner higher market share. For instance, In May 2022,  Guardant Health, Inc. a leading precision oncology company, announced the availability of Shield™, the company’s first blood-based test for the detection of early-stage colorectal cancer (CRC).

Interest of Private Equity Firms in Liquid Biopsy Market

To leverage upcoming growth opportunities in the global liquid biopsy market, private equity firms are making investments in potentially high-growth areas/companies in this space. For instance, In May 2022, BioMarks Diagnostics secured $1.5 million from a private financing round to accelerate the commercialization of its liquid biopsy technology.

Get Detailed Research Insights on Liquid Biopsy Market @ https://meditechinsights.com/liquid-biopsy-market/